Thomas J. Semrad

Thomas J. Semrad

Auto-generated profile, based on publicly available information

Thomas J. Semrad

Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee, CA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2007 in Journal of Neurosurgery
Verified
Journal Article
Closed access
TSThomas J. Semrad
Thomas J. Semrad
RORobert O'DOnnell
Robert O'DOnnell
TWTed Wun
Ted Wun
HCHelen Chew
Helen Chew
DHDanielle Harvey
Danielle Harvey
RWRichard H. White
Richard H. White
Object: The authors sought to define the incidence of symptomatic venous thromboembolism (VTE) in patients harboring malignant gliomas. Methods: The authors conducted a retrospective analysis of data obtained in all cases of malignant glioma diagnosed in California during a 6-year period; the occurrence of a VTE was identified using linked hospital discharge data. The Cox proportional hazard model was used to analyze the association of specific risk factors with the development of a VTE or death within 2 years of the cancer diagnosis. Among 9489 cases, the 2-year cumulative incidence of VTE was 7.5% (715 cases), with a rate of 16.1 events per 100 person-years during the first 6 months. Three hundred ninety-one (55%) of these 715 cases were diagnosed within 61 days of major neurosurgery. Risk factors for VTE included older age (hazard ratio [HR] 2.6, confidence interval [CI] 2.0–3.4 for age range 65–74 years compared with ≤ 45 years), glioblastoma multiforme histology (HR 1.7, CI 1.4–2.1), three or more chronic comorbidities (HR 3.5, CI 2.8–4.3 [compared with no comorbidity]), and neurosurgery within 61 days (HR 1.7, CI 1.3–2.3). Patients in whom a VTE was present were at higher risk of dying within 2 years (HR 1.3, CI 1.2–1.4). In a nested case–control analysis of all VTE cases, there was no association between insertion of a vena cava filter and the risk of a recurrent VTE. Conclusions: In patients harboring a glioma there was a very high incidence of symptomatic VTEs, particularly within 2 months of neurosurgery. The development of a VTE was associated with a 30% increase in the risk of death within 2 years. Further studies are needed to determine if risk stratification and the use of medical prophylaxis after neurosurgery improves outcomes.

1 March 2012 in Clinical Lung Cancer
Verified
Journal Article
Closed access
TSThomas J. Semrad
Thomas J. Semrad
PMPhilip C. Mack
Philip C. Mack

10 January 2011 in Cancer
Verified
Journal Article
Open access
PDF file
TSThomas J. Semrad
Thomas J. Semrad
DTDaniel J. Tancredi
Daniel J. Tancredi
LBLaura‐Mae Baldwin
Laura‐Mae Baldwin
PGPamela Green
Pamela Green
JFJoshua J. Fenton
Joshua J. Fenton
BACKGROUND: The Medicare population has documented racial/ethnic disparities in colorectal cancer (CRC) screening, but it is unknown whether these disparities differ across geographic regions.METHODS: Among Medicare enrollees within 8 US states, we ascertained up‐to‐date CRC screening on December 31, 2003 (fecal occult blood testing in the prior year or sigmoidoscopy or colonoscopy in the prior 5 years). Logistic regression models tested for regional variation in up‐to‐date status among white versus different nonwhite populations (blacks, Asian/Pacific Islanders [APIs], Hispanics). We estimated regression‐adjusted region‐specific prevalence of up‐to‐date status by race/ethnicity and compared adjusted white versus nonwhite up‐to‐date prevalence across regions by using generalized least squares regression.RESULTS: White versus nonwhite up‐to‐date status varied significantly across regions for blacks (P = .01) and APIs (P < .001) but not Hispanics (P = .62). Whereas the white versus black differences in proportion up‐to‐date were greatest in Atlanta (Georgia), rural Georgia, and the San Francisco Bay Area of California (range, 10%‐16% differences, blacks<whites); there were no significant white versus black differences in Connecticut, Seattle (Washington) or Iowa. Whereas APIs had significantly lower up‐to‐date prevalence than whites in Michigan and the California regions of San Francisco, Los Angeles, and San Jose (range, 4%‐15% differences, APIs<whites), APIs in Hawaii had higher up‐to‐date status than whites (52% vs 38% P < .001). White versus Hispanic differences were substantial but homogeneous across regions (range, 8%‐16% differences, Hispanics<whites). In contrast to nonwhites, there was little geographic variation in up‐to‐date status among whites.CONCLUSIONS: Significant geographic variation in up‐to‐date status among black and API Medicare enrollees is associated with heterogeneous racial/ethnic disparities for these groups across US regions. Cancer 2011. © 2011 American Cancer Society.

5 August 2014 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
TSThomas Semrad
Thomas Semrad
ABAfsaneh Barzi
Afsaneh Barzi
HLHeinz-Josef Lenz
Heinz-Josef Lenz
IHIrene M. Hutchins
Irene M. Hutchins
EKEdward J. Kim
Edward J. Kim
PLPrimo N. Lara
Primo N. Lara

20 April 2026 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MSManish A Shah
Manish A Shah
EKErin B. Kennedy
Erin B. Kennedy
DDDana Deighton
Dana Deighton
MJMinaxi Jhawer
Minaxi Jhawer
KKKunal C. Kadakia
Kunal C. Kadakia
LRLakshmi Rajdev
Lakshmi Rajdev
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases, or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and Appendix 2 (online only) for more . PURPOSE: To provide updated recommendations for immunotherapy and targeted therapy for patients with advanced gastroesophageal cancer. METHODS: ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice. RESULTS: Twelve newly published or updated phase III randomized controlled trials met the inclusion criteria for the systematic review. RECOMMENDATIONS: The target population for these recommendations is patients with unresectable locally advanced, advanced, or metastatic gastroesophageal cancer. Results from testing for actionable biomarkers should be available as soon as possible to inform treatment decision making. Immunotherapy with doublet chemotherapy is recommended for patients with proficient mismatch repair (pMMR)/microsatellite stable (MSS) human epidermal growth factor receptor 2 (HER2)–negative gastroesophageal adenocarcinoma or squamous cell carcinoma and PD-L1 expression ≥1; patients with higher PD-L1 expression are more likely to benefit from immunotherapy. Zolbetuximab is recommended for patients with gastroesophageal adenocarcinoma, PD-L1 <1, and positive CLDN18.2 expression. Patients with dual PD-L1 and CLDN18.2 positivity should engage in shared decision making, considering the factors outlined in the guideline. Doublet chemotherapy alone is recommended for patients who are not positive for actionable biomarkers or are not considered candidates for targeted therapy or immunotherapy. For patients with pMMR/MSS HER2-positive gastric/gastroesophageal junction (GEJ) adenocarcinoma, trastuzumab and doublet chemotherapy is recommended; for patients with PD-L1 expression ≥1, the addition of pembrolizumab is recommended. Immunotherapy alone or with doublet chemotherapy is recommended for patients with mismatch repair deficient/microsatellite instability–high gastroesophageal cancer. Second-line therapy options include ramucirumab with paclitaxel, trastuzumab deruxtecan for HER2-positive gastric/GEJ adenocarcinoma, and immunotherapy for PD-L1 ≥1 esophageal squamous cell carcinoma after first-line combination chemotherapy without immunotherapy. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .

1 January 2015 in Journal of Thoracic Oncology
Verified
Journal Article
Open access
PDF file
PLPrimo N. Lara
Primo N. Lara
JMJames Moon
James Moon
MRMary W. Redman
Mary W. Redman
TSThomas J. Semrad
Thomas J. Semrad
KKKaren Kelly
Karen Kelly
DGDavid R. Gandara
David R. Gandara
Background Extensive-stage small-cell lung cancer (SCLC) patients who progress after platinum-based chemotherapy are traditionally categorized as platinum sensitive (progression ≥ 90 days from last platinum dose) or refractory (progression < 90 days), a practice arising from seminal observations of worse survival in refractory patients. Subsequent trials accounted for platinum sensitivity, resulting in higher sample sizes and increased resource use. Methods To assess whether platinum-sensitivity status remains associated with outcomes, patient-level data from recent Southwest Oncology Group trials in second- and/or third-line extensive-stage SCLC were pooled. Hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS) accounting for platinum sensitivity were calculated using unadjusted and adjusted Cox Proportional Hazard models. Recursive partitioning was performed to define prognostic risk groups. Results Of 329 patients, 151 were platinum sensitive and 178 refractory. HRs from unadjusted Cox PFS and OS models for refractory versus sensitive disease were 1.0 (95% confidence interval, 0.81–1.25; p = 0.98) and 1.24 (0.99–1.57; p = 0.06), respectively. Adjusted Cox models showed that only elevated serum lactate dehydrogenase (HR, 2.04; p < 0.001), males (HR, 1.36; p = 0.04), performance status of 1 (HR, 1.25; p = 0.02), and weight loss greater than or equal to 5% (1.53, p = 0.01) were independently associated with OS. Platinum-sensitivity status was not associated with PFS (HR, 1.11; p = 0.49) or OS (HR, 1.25; p = 0.14), except in a model that excluded 36 patients who received more than one prior chemotherapy regimen (HR, 1.34; p = 0.049). Prognostic groups with differential OS outcomes (high, intermediate, and poor risk) were identified. Conclusions Platinum-sensitivity status may no longer be strongly associated with PFS or OS in at least one multivariate model. Validation of prognostic risk groups identified here is warranted. These data have critical implications in the design of future SCLC trials.